1. Volume 370, Issue 9600, Pages 1687-1697 (November 2007)
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial 
Prof AC Keech, FRACP, Prof P Mitchell, FRANZCO, PA Summanen, FEBO, J O'Day, FRANZCO, Prof TME Davis, MRCP, MS Moffitt, DipTc, Prof M-R Taskinen, MD, Prof RJ Simes, FRACP, D Tse, PhD, E Williamson, PhD, A Merrifield, PhD, Prof LT Laatikainen, FEBO, MC d'Emden, FRACP, DC Crimet, MD, RL O'Connell, MMedStat, Prof PG Colman, FRACP 
The Lancet 
Volume 370, Issue 9600, Pages (November 2007)
DOI: /S (07)
Copyright © 2007 Elsevier Ltd Terms and Conditions

2. Figure 1 Trial profile (A) FIELD study. (B) Ophthalmology substudy.
The Lancet  , DOI: ( /S (07) )
Copyright © 2007 Elsevier Ltd Terms and Conditions

3. Figure 2
Cumulative risk curves of time to event of any first laser treatment, by treatment group
Macular oedema indicates laser treatment where the macula was involved; proliferative retinopathy shows cases without macular involvement; all retinopathy includes all first instances of laser treatment for any diabetic retinopathy.
The Lancet  , DOI: ( /S (07) )
Copyright © 2007 Elsevier Ltd Terms and Conditions

4. Figure 3 Effect of fenofibrate on first and all laser treatment events
Counts for each underlying pathology are shown; for first events, a patient was counted only once under each type of pathology listed; for all events, all courses of laser treatment for each type of pathology are counted (Poisson method). *Without macular involvement.
The Lancet  , DOI: ( /S (07) )
Copyright © 2007 Elsevier Ltd Terms and Conditions

5. Figure 4 Ophthalmology substudy
(A) Distribution of patients and proportion of laser treatment events by ETDRS grading of retinopathy at baseline; (B) number of laser treatment events in each treatment group by ETDRS grading of retinopathy at baseline.
The Lancet  , DOI: ( /S (07) )
Copyright © 2007 Elsevier Ltd Terms and Conditions